Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Scientific and technological issues in alternatives research in drug development and Union politics (START-UP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Coordination and support actions
Countries involved: Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2010-02-28
Duration (months): 24.0
Total project cost (EUR): 355988.0
EU funding (EUR): 317964.0
Participants: 2
Project status: CLOSED

Scientific and technological issues in alternatives research in drug development and Union politics START-UP The START-UP project concerns the identification and proposals to abolish bottlenecks in the 3Rs approach in pharmaceutical discovery and development. The goal of the project is organising 3 Workshops to determine the state of the art of each of the 3Rs in the EU, assess European strength and gaps in 3Rs and identify rate limiting steps on a scientific and technological level, resulting in a Consensus Paper containing concepts and suggestions for a Road Map for future research. Stakeholders (among them European Pharmaceutical Industries) have identified bottlenecks in drug development and in the integration of in vitro methods. Early identification of wrong candidates for further development and avoiding efforts for under-performing candidates are essential for the competitiveness of European Industry. Identification of bottlenecks in the implementation of the 3Rs in drug R&D should help identifying the best in vitro and in vivo systems, and to speed up the drug development process. Existing hurdles in the scientific, technological, ethical, regulatory and political level, play a substantial role and are rate-limiting in developing new drugs, including biological entities. The project is structured around 3 Workshops, preceded by 2 Expert Meetings redefining and prioritising current bottlenecks in 3Rs methodology, drug discovery and development. The limitations and gaps of each phase will be addressed, e.g. many cell systems do not have the required stability for genomics, proteomics or metabonomics ; many current cell systems lack crucial bioactivation capability. Thus, the status of satisfactory “predictive” pharmacology and toxicology in vitro has not yet been reached. The final goal is a Consensus Document .Thereupon, a Road Map to implement the strategy for a better integration of 3Rs in the EU drug discovery and development strategy will be proposed.

Keywords: bottlenecks in 3rs,pharmaceutical discovery and development,alternative methods,refinement,reduction,replacement,drug discovery,in vitro experimentation
Biogeographic Relationships Among the Mountain Ranges of Europe, Middle East and Asia: Evolution, Phylogeny and Phylogeography of the Genus Wulfenia (EUROEAST)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Croatia
Call:  (FP7-PEOPLE-2007-2-2-ERG, 2007)
Start date: 2008-03-14
End date: 2010-09-13
Duration (months): 30.0
Total project cost (EUR): 37500.0
EU funding (EUR): 37500.0
Participants: 1
Project status: CLOSED

Mountain ranges in the circum-Mediterranean area, with the Balkan Peninsula in particular, are hotspots of European biodiversity, with the most remarkable element being the high level of endemism in the Balkan Peninsula. With the intention of explanation of this phenomenon, we use a model plant genus Wulfenia to address the objectives within the proposed project: (a) ascertainment of molecular phylogenetic hypoteses on the relationships of the study genus both to its closest relatives as well as within the genus; (b) testing the Pleistocene speciation hypothesis: long distance dispersal or vicarism?; (c) ascertainment of comparitive phylogeographic hypotheses within species and species groups; (d) identifying the putative centres of origin of the study group based on phylogenetic and phylogeographic patterns; (e) identifying the migration paths between the disjunct populations; (f) defining the timing of the colonisation of the present disjunct distribution range. All the material of the genus Wulfenia will be collected in the field, while that of the related genera also herbarium material will be used. Research will be carried out applying both classical [e.g. morphometrics, cladistics] as well as modern molecular methods [DNA-sequencing, cpDNA haplotype analysis, DNA-fingerprinting (AFLP), biogeographical analysis, molecular dating]. Our results, which are also of high relevance for conservation purpouses, will significantly contribute to a broader basis addressing the questions going beyond the study group, e.g., biogeography of the Middle East, southern Europe and Asia.

Keywords: evolution,balkan peninsula,middle east,biogeography,botany
New Frontiers in Spintronics (NEWSPIN)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Condensed matter physics
Countries involved: Netherlands
Call:  (ERC-2007-StG, 2007)
Start date: 2008-09-01
End date: 2013-08-31
Duration (months): 60.0
Total project cost (EUR): 876000.0
EU funding (EUR): 876000.0
Participants: 1
Project status: CLOSED

The aim of this theory proposal is to develop the research field of spintronics in three new directions - i) antiferromagnetic metals, ii) helimagnets, and iii) ultracold quantum gases - unified by the fact that it is a priori clear that new concepts have to be developed in understanding their spintronics phenomena. The central scientific challenge is understanding transport of a nonconserved quantity, i.e., spin, and its nonconserved current, i.e., the spin current. The proposal capitalizes in part on the PI’s experience with both spintronics and cold atoms to cross-fertilize these sub-disciplines of condensed-matter physics. i) The first focus of the proposal, motivated by experimental follow-ups of the PI’s pioneering theory work, is to theoretically study current-driven magnetization dynamics in antiferromagnetic metals. These materials are very promising for applications in ultrahigh-density information storage technology. ii) The second focus is to study the influence of current on the magnetic state of a helimagnet. The dynamics of the magnetization spiral in a helimagnet can be viewed as motion of a series of domain walls. In addition to its intrinsic fundamental interest this study will therefore shed light on the ongoing issues in current-driven domain wall motion, such as intrinsic versus extrinsic pinning of domains, and the role of intrinsic spin-orbit coupling. iii) The third and last focus of the proposal is to study analogues of spintronics phenomena with cold atoms, exploiting the well-understood microscopic description of these systems to quantum engineer model systems for spintronics, as well as their possibilities to go beyond conventional electronic condensed-matter physics. In particular the prospect for spin currents to be carried by bosonic particles opens up new research directions. This study develops new trends in spin-dependent transport phenomena and current-induced order-parameter dynamics.

Keywords: spintronics,antiferromagnetism,helimagnet,bose-einstein condensation
EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances (EURIPIDES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Austria,Germany,Germany,France,Netherlands,Netherlands,Greece,Netherlands,Denmark
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-02-01
End date: 2012-07-31
Duration (months): 54.0
Total project cost (EUR): 9086523.4
EU funding (EUR): 6994850.0
Participants: 14
Project status: CLOSED

We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against concentration gradients across the blood-brain barrier (BBB). Overactivity of these efflux transporters results in inadequate access of CNS drugs to their targets and hampers the build up of adequate tissue levels of these drugs in the brain, greatly limiting their therapeutic efficacy. As such, this "transporter hypothesis" of drug resistance is applicable to a broad range of CNS drugs and patients with a variety of CNS diseases who critically depend on these drugs. Efflux transporters may also influence brain elimination of Aβ, the hallmark of Alzheimer’s disease (AD). Impaired multidrug transporter function with reduced clearance of Aβ could lead to accumulation within the extracellular space, contributing to the pathogenesis of AD. We will determine the contribution of multidrug transporters to impaired brain uptake of drugs for the prediction of therapeutic responses, or the contribution of impaired transporter function to reduced clearance of toxic substances for the early in-vivo diagnosis of AD. Circumvention of pharmacoresistance, or increasing clearance, may involve inhibitors of multidrug transporters or sophisticated alternative therapies, but demonstration of overexpression or underactivity of transporter function is an essential and necessary first step. An in-vivo imaging biomarker of multidrug transporter function is essential for identifying altered transporter activity in individual patients. If a relation between overexpression and therapy resistance, or underactivity and AD, can be demonstrated, such a biomarker will provide the means for predicting treatment response, or early diagnosis, in individual patients.

Keywords: pharmacoresistance,p-glycoprotein,molecular imaging,blood-brain-barrier,prediction of treatment response,neurodegeneration,polymorphisms
Discovery of novel cancer serum biomarkers based on aberrant post translational modifications of O-glycoproteins (O-PTM-Biomarkers) and their application to early detection of cancer (O-PTM-BIOMARKERS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Denmark,France,Germany,Portugal,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-03-31
Duration (months): 39.0
Total project cost (EUR): 3847340.2
EU funding (EUR): 2848153.0
Participants: 9
Project status: CLOSED

Early detection accomplished through an efficient screening programme remains the most promising approach to improve the long-term survival of cancer patients. Therefore there is a pressing need for the development of biomarkers, which detect the early changes for cancers where clinical symptoms only appear when the cancer has progressed, and treatment is ineffective. Our proposal, which addresses this problem at the European level, combines two unique features: i) large unique collections of sera with the potential for evaluation of diagnostic serum biomarkers with high statistical power, and ii) a novel technological approach involving specific immuno-detection of cancer-associated Post-Translationally Modified (PTM) glycoproteins in serum and of auto-antibodies to these glycoproteins. Glycosylation of proteins is one of the most abundant and complex forms of post translation modifications and the most important for the cell surface and secreted proteomes. O-glycosylation (O-PTM) is always altered in carcinomas, creating novel O-PTM epitopes which induce auto-antibodies. Our Main Objectives are therefore to:- 1.Use a novel glycopeptide microarray technology to identifiy, evaluate and validate an O-PTM auto-antibody signature as an early diagnostic biomarker, focusing on breast, ovarian, pancreatic and lung cancers. 2. Develop and validate novel ELISA-type assays for cancer specific glycoforms of the MUC1 and MUC16 glycoproteins (targets of current serum biomarker assays). The project brings together a Consortium with participants from 5 member States to fully exploit the potential of the unique serum banks at a European level by A. Integrating the expertise of world leaders in Glycobiology with Cancer Physicians and experts in biomarker assays. B. Establishing a functional interaction between Academic groups and Commercial enterprises committed to improving cancer therapy and diagnosis.

Keywords: serum biomarkers,cancer,post-translational modification,o-linked glycosylation,auto-antibody signature,cancer associated glycoforms,glycopeptide microarrays,glycoproteomics,early diagnosis
REvolutionary Approaches and Devices for Nucleic Acid Analysis (READNA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,Sweden,United Kingdom,United Kingdom,Germany,Netherlands,Sweden,United Kingdom,Germany,Denmark,France,Netherlands,Germany,Germany,France,Sweden,Spain,Netherlands
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-06-01
End date: 2012-11-30
Duration (months): 54.0
Total project cost (EUR): 15753593.54
EU funding (EUR): 11992319.0
Participants: 20
Project status: CLOSED

The REvolutionary Approaches and Devices for Nucleic Acid analysis – READNA – consortium is composed of researchers from 10 academic institutions, 5 SMEs and 3 large companies. The goals of the READNA consortium are to revolutionize nucleic acid analysis methods, by 1) improving elements necessary to use the currently emerging generation of nucleic acid sequencers in a meaningful and accessible way, 2) providing methods that allow in situ nucleic acid analysis and methods capable of selectively characterizing mutant DNA in a high background of wildtype DNA, 3) combining RNA and DNA analysis in a single analytical device, 4) providing technology to efficiently analyze DNA methylation (genome-wide, with high resolution and in its long-range context), 5) implementing novel concepts for high-throughput HLA-screening, 6) developing fully integrated solutions for mutational screening of small target regions (such as for screening newborns for cystic fibrosis mutations), 7) developing a device for screening multiple target regions with high accuracy, and 8) implementing strategies for effective and high-resolution genotyping of copy number variations. An important part of READNA is dedicated to the development of the next generation of nucleic analysis devices on individual DNA molecules by stretching out nucleic acid molecules in nanosystems, using alpha-hemolysing nanopores and carbon nanotubes. These approaches will benefit from improved interrogation and detection strategies which we will develop. Our methods and devices will boost the possibilities of genetic research by closing in on the target of 1000 Euros for the sequence of a complete human genome, while at the same time leading a revolution in cost-effective, non-invasive early screening for diseases such as cancer.

Keywords: sequencing,genotyping
Developing high-thoughput bioassays for human cancers in zebrafish. (ZF-CANCER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Belgium,United Kingdom,Netherlands,Germany,Austria,Spain,Spain
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2011-03-31
Duration (months): 36.0
Total project cost (EUR): 4197454.78
EU funding (EUR): 2991793.0
Participants: 9
Project status: CLOSED

Recently the zebrafish has emerged as a new important system for cancer research because the zebrafish genome contains all orthologs of human oncogenes and forms tumors with similar histopathological and gene profiling features as human tumors. The zebrafish provides an in vivo vertebrate model for identifying novel mechanisms of cancer progression and for development of new anticancer compounds in a time- and cost-effective manner. The ZF-CANCER project aims to develop high-throughput bioassays for target discovery and rapid drug screenings applicable in preclinical validation pipelines. Fluorescently labelled human and zebrafish cancer cells will be implanted (xenogenic and allogenic transplantation) into zebrafish embryos transgenic for a GFP-vascular marker and quantitative, multi-colour fluorescent intravital bio-imaging of tumour progression will be set up as the readout. Because of its amenability to genetic manipulation and optical transparency, the zebrafish is currently the only vertebrate model that allows the simultaneous in vivo imaging of all hallmarks of cancer progression including cell survival, proliferation, migration and induction of angiogenesis. The combination of visual, non- invasive monitoring in translucent host embryos with powerful RNA interference technology, successfully developed for human cancer cells will enable identification of novel targets in a wide variety of human cancers. Automation of these fluorescent readouts will accelerate the screening process with chemical libraries to discover new compounds involved in different aspects of cancer progression and inhibition. In the case study, a selected panel of genes and lead compounds will be screened on a high-throughput platform, possibly resulting in the identification of important anti-tumour drugs relevant for human cancer therapy. Fundamental knowledge, tools and technical expertise gained from ZF-CANCER will be commercially exploited by one company and two high-tech SMEs.

Keywords: zebrafish,oncogenic cell implants,high-throughput bioassays,anti-tumor target and drug discovery
Investigation of the molecular pathogenesis and pathophysiology of Disorders of Sex Development (DSD) (EURODSD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,France,United Kingdom,United Kingdom,Netherlands,United Kingdom,Italy,Sweden,Germany,France,Germany,Germany,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2011-10-31
Duration (months): 42.0
Total project cost (EUR): 3894132.34
EU funding (EUR): 2989198.0
Participants: 14
Project status: CLOSED

Disorders of Sex Development (DSD) constitute a group of rare to very rare mostly heritable disorders affecting the genito-urinary tract and in most instances also the endocrine-reproductive system. We hypothesize that stringent and stepwise analysis of cases with DSD will result in a systematic and reliable discovery of DSD-relevant biochemical, genetic and functional profiles, allowing for the detection of new diagnostic markers, both in steroid biosynthesis as well as in genetics to provide the basis for explaining the nature of these disorders. Characterization of the functional aspects of androgen action as the main basis for sex-related phenotype will improve the understanding of the pathophysiology of DSD phenotypes. This will allow for better decision-making in gender assignment and therapeutic approaches to DSD as well as improve gender medicine in general.

Keywords: rare diseases,disorders of sex development (dsd),endocrinology,molecular genetics,disorders affecting the genito-urinary tract
Monoclonal ANTIbody-targeted CARBon nanobues against cancer (ANTICARB)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,Belgium,France,Italy,Germany,Greece,Hungary
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2011-08-31
Duration (months): 42.0
Total project cost (EUR): 3987793.4
EU funding (EUR): 2967008.0
Participants: 8
Project status: CLOSED

ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents – antibodies – with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology.

Keywords: improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy
European Network for the Study of Orphan Nephropathies (EUNEFRON)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,France,Denmark,Netherlands,Germany,Switzerland,Italy,United Kingdom,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2012-04-30
Duration (months): 48.0
Total project cost (EUR): 3922733.34
EU funding (EUR): 2990000.0
Participants: 10
Project status: CLOSED

In this proposal, we have mobilized a critical mass of expertise to investigate, on a Europe-wide scale, the natural history and pathophysiology of rare inherited diseases affecting important structures of the kidney. The project will use and develop multiple models (in vitro and in vivo) with the aim to develop preventive, diagnostic and therapeutic interventions that should alleviate the burden of these diseases, particularly in children. A central part of the proposal is the creation of a European registry and a network of genetic laboratories to foster a tight interaction between physicians and researchers, promote clinical and basic research, and ensure the efficient dissemination of knowledge. By increasing our knowledge of these rare diseases, the EUNEFRON project will also yield new insights into basic processes relevant for the general population (progression of renal disease, blood pressure control, prevention of renal stones, effect of gender and ageing, etc…), the complex relationship between different nephron segments, and the multi-systemic involvement of renal diseases.

Keywords: rare diseases,genetics,kidney,orphan nephropathies,pathophysiology,natural course of disease,renal failure,children health